Randomized Study to Compare Valsartan +/- HCTZ Versus Amlodipine +/- HCTZ Strategies to Maximize Blood Pressure Control

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2009 Nov 10

PMID 19898644

Citations 3

Authors

Dion Zappe

Cheraz Cherif Papst

Philippe Ferber

Affiliations

Soon will be listed here.

Abstract

Objective: Delays in achieving blood pressure (BP) control may increase morbidity and mortality in patients with hypertension. Thus, deciding which antihypertensive agent to use and at what dosage, in addition to determining when to initiate combination therapy and which agents to combine, is important for achieving BP control.

Methods: This randomized, double-blind, 14-week study was conducted to compare the efficacy and tolerability of various doses of valsartan +/- hydrochlorothiazide (HCTZ) versus amlodipine +/- HCTZ for maximizing BP control in 1,285 patients with uncontrolled hypertension. Patients with stage 1 hypertension and naïve to antihypertensive therapy (33.9%) started valsartan 160 mg or amlodipine 5 mg. Treatment-naïve patients with stage 2 hypertension (13.5%) or those uncontrolled on current antihypertensive monotherapy (52.6%) started valsartan 160 mg/HCTZ 12.5 mg or amlodipine 10 mg. At weeks 4, 8, and 11, patients not achieving BP control were up-titrated (maximum: valsartan 320 mg/HCTZ 25 mg, amlodipine 10 mg/HCTZ 25 mg).

Results: At study end, 78.8% of patients on valsartan +/- HCTZ were controlled (BP <140/90 mmHg) and still on study medication versus 67.8% on amlodipine +/- HCTZ (P < 0.0001). Amlodipine-treated patients had a higher incidence of peripheral edema (22.4% vs 2.2%) and associated discontinuations (7.3% vs <1%). Initiating therapy earlier with valsartan/HCTZ, rather than titrating monotherapy to its maximum dose before adding a second agent, was superior to amlodipine monotherapy or amlodipine +/- HCTZ for achieving BP control, and avoided excessive treatment adjustments and maintained tolerability.

Citing Articles

Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.

Al Balushi K, Habib J, Al-Zakwani I Med Princ Pract. 2012; 22(3):265-9.

PMID: 23235349 PMC: 5586736. DOI: 10.1159/000345389.

Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.

Raij L, Egan B, Zappe D, Purkayastha D, Samuel R, Sowers J J Clin Hypertens (Greenwich). 2011; 13(10):731-8.

PMID: 21974760 PMC: 8108811. DOI: 10.1111/j.1751-7176.2011.00499.x.

Pharmaceutical composition of hydrochlorothiazide:β-cyclo-dextrin: preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation.

Pires M, Dos Santos R, Sinisterra R Molecules. 2011; 16(6):4482-99.

PMID: 21623317 PMC: 6264165. DOI: 10.3390/molecules16064482.

References

Osterloh I . The safety of amlodipine. Am Heart J. 1989; 118(5 Pt 2):1114-9; discussion 1119-20. DOI: 10.1016/0002-8703(89)90838-7. View

Oparil S, Yarows S, Patel S, Fang H, Zhang J, Satlin A . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370(9583):221-229. DOI: 10.1016/S0140-6736(07)61124-6. View

Wagstaff A . Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006; 66(14):1881-901. DOI: 10.2165/00003495-200666140-00011. View

Elliott W . What factors contribute to the inadequate control of elevated blood pressure?. J Clin Hypertens (Greenwich). 2008; 10(1 Suppl 1):20-6. PMC: 8110129. DOI: 10.1111/j.1524-6175.2007.08028.x. View

Nickenig G, Ostergren J, Struijker-Boudier H . Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotensin Aldosterone Syst. 2006; 7 Suppl 1:S1-7. DOI: 10.3317/jraas.2006.017. View

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

Sica D . Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations. J Clin Hypertens (Greenwich). 2007; 9(1):78-86. PMC: 8109912. DOI: 10.1111/j.1524-6175.2007.6359.x. View

Lacourciere Y, Wright Jr J, Samuel R, Zappe D, Purkayastha D, Black H . Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Press Monit. 2009; 14(3):112-20. DOI: 10.1097/MBP.0b013e32832a9da7. View

Ruilope L, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D . Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005; 27(5):578-87. DOI: 10.1016/j.clinthera.2005.05.006. View

10.

Hermida R, Ayala D, Khder Y, Calvo C . Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther. 2008; 30(1):108-20. DOI: 10.1016/j.clinthera.2008.01.012. View

11.

Malacco E, Vari N, Capuano V, Spagnuolo V, Borgnino C, Palatini P . A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003; 25(11):2765-80. DOI: 10.1016/s0149-2918(03)80332-6. View

12.

Verdecchia P, Angeli F . Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther. 2004; 26(4):460-72. DOI: 10.1016/s0149-2918(04)90049-5. View

13.

Palatini P, Malacco E, Di S, Carretta R, Dorigatti F, Bertocchi F . Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol. 2002; 57(11):765-70. DOI: 10.1007/s00228-001-0393-6. View

14.

Jamerson K, Weber M, Bakris G, Dahlof B, Pitt B, Shi V . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23):2417-28. DOI: 10.1056/NEJMoa0806182. View

15.

TYLER H . Amlodipine: an effective once-daily antihypertensive agent. J Hum Hypertens. 1991; 5 Suppl 1:61-6. View

16.

Weir M . Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich). 2006; 8(2):99-105. PMC: 8109700. DOI: 10.1111/j.1524-6175.2005.04648.x. View

17.

Weir M, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R . Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007; 9(2):103-12. PMC: 8110071. DOI: 10.1111/j.1524-6175.2007.06415.x. View

18.

Brown M, Cruickshank J, Dominiczak A, Macgregor G, Poulter N, Russell G . Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003; 17(2):81-6. DOI: 10.1038/sj.jhh.1001511. View

19.

Neutel J . The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs. 2002; 17(2):81-8. DOI: 10.1111/j.0889-7204.2002.01308.x. View

20.

Palatini P, Mugellini A, Spagnuolo V, Santonastaso M, Ambrosia G, Caiazza A . Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit. 2004; 9(2):91-7. DOI: 10.1097/00126097-200404000-00006. View